AstraZeneca’s Calquence fails to meet primary efficacy endpoint in phase II Covid-19 trials

This article was originally published here

The addition of Calquence to best supportive care (BSC) has failed to increase the proportion of patients who remained alive and free of respiratory failure. Calquence, the next-generation

The post AstraZeneca’s Calquence fails to meet primary efficacy endpoint in phase II Covid-19 trials appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply